Outstanding authors providing details on their research and institution, elaborating on interesting findings and discussing potential new directions of themselves and others as a result of their research.

Interviews with Outstanding Authors

Full text - http://bit.ly/2duVAwX

Oncotarget | Interview with Dr. Joyce Schroeder - Professor Molecular & Cellular Biology and BIO5 Institute Chief Scientific Officer at the Arizona Cancer Therapeutics Carcinogenesis Department of Molecular and Cellular Biology University of Arizona, Tucson, Arizona speaking about their Cover Paper in Oncotarget Volume 7 Issue 38 "Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migration" 

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Schroeder - Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migra...

Full text - http://bit.ly/2pgqWjW

Oncotarget | Interview with Dr. Kelber from the Department of Biology, California State University Northridge, Northridge, CA talking about their featured cover paper in Oncotarget Volume 8 Issue 4 "A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts" 

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Kelber - A novel method for RNA extraction from FFPE samples reveals significant differences in...

Full text - http://bit.ly/1TYK5Rg

Oncotarget | Interview with Dr. Markus D. Siegelin & Dr. Georg Karpel-Massler - Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, U.S.A. talking about their cover paper published in Volume 7 Issue 23 of Oncotarget called "Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo"

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Siegelin & Karpel-Massler - Metabolic reprogramming of glioblastoma cells by L-asparaginase sensit..

Full text - http://bit.ly/2ocULhq

Interview with Dr. Raz with the Department of Orthopaedics, Leiden University Medical Center, in the Leiden Netherlands talking about their featured cover paper in Oncotarget Volume 7 Number 8 "Molecular signatures of age-associated chronic degeneration of shoulder muscles" 

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Raz - Molecular signatures of age-associated chronic degeneration of shoulder muscles

Full text - http://bit.ly/28Ncmoy

Oncotarget | Interview with Dr. René Bernards & Diede Brunen - Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands - talking about their cover paper published in Volume 7 Issue 25 of Oncotarget called "Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling" 

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Bernards - Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback a...

"Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy"

The research team’s analyses revealed ultra-hypermutation, defined as greater than 100 mutations per megabase, in this patients cancer, which was further characterized by the presence of three distinct mutational signatures including UV radiation and APOBEC signatures.

Truncal alterations, defined as being present in all clonal tumor cell populations, in this patients cancer include point mutations in TP53 and CDKN2A and amplifications of c-KIT and APOBEC3A-H, which are likely driver mutations.

Dr. Sameek Roychowdhury from the Department of Internal Medicine, Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA said, "Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare malignancy of dendritic cell origin with approximately 100 cases reported to date"

Localized IDCS constitutes 47% of cases and manifests as painless lymphadenopathy, most commonly involving the cervical and axillary nodes.

Isolated extra-nodal disease occurs in 25% of cases, involving the liver, lung, spleen, bone marrow and gastrointestinal tract .

Distant metastases occur in 39% of cases and most frequently involved lymph nodes, lung, liver and bone marrow .

Here they performed whole exome sequencing of multiple tumors obtained through rapid research autopsy of a patient with metastatic IDCS. In August 2016, the patient underwent modified radical right neck dissection and partial submandibular gland excision with one level I lymph node demonstrating complete tumor involvement and suspicious for extranodal extension; remaining lymph nodes from levels II, III and IV were negative for tumor infiltration.

In the future, it will be important to study additional patients with this and other rare cancers with hypermutation.

The Roychowdhury research team concluded, “Finally, the broader clinical implication of our results is that although patients with hypermutated cancer, originating from either somatic or germline genomic aberrations, are more likely to benefit from checkpoint inhibition, research is still needed to stratify these patients to maximize therapeutic efficacy and identify the different genetic determinants of primary or acquired resistance to immunotherapy.”

Full text - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=26352&path%5B%5D=82077
 
Correspondence to - Sameek Roychowdhury email: Sameek.Roychowdhury@osumc.edu

Keywords - tumor heterogeneity, research autopsy, hypermutation
 
About Oncotarget
 
Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology, including Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes among others.
 
Oncotarget is published by Impact Journals LLC.
 
To learn more about Oncotarget, please visit http://www.ImpactJournals.com

Facebook - http://bit.ly/2xznxjV
Twitter - http://bit.ly/2xzWvsu
LinkedIn - http://bit.ly/2xzJ6kc
Pintrest - http://bit.ly/2xzX8SS
Reddit - http://bit.ly/2hoxI0N

Oncotarget Audio Interview with Sameek Roychowdhury & Hui-Zi Chen

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Oncotarget Audio Interview with Sameek Roychowdhury & Hui-Zi Chen

Oncotarget Podcast